Lamivudine/tenofovir
Combination of
LamivudineNucleoside reverse transcriptase inhibitor
Tenofovir disoproxilNucleotide reverse transcriptase inhibitor
Clinical data
Trade namesCimduo, Temixys
AHFS/Drugs.comMonograph
MedlinePlusa618039
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
KEGG

Lamivudine/tenofovir disoproxil, sold under the brand name Cimduo among others, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS in adults and children weighing more than 35 kilograms (77 lb).[1][3] It contains lamivudine and tenofovir disoproxil.[1] It is taken by mouth.[1]

Lamivudine/tenofovir was approved for medical use in the United States in February 2018.[1][4]

References

  1. 1 2 3 4 5 "Cimduo- lamivudine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. 22 March 2018. Retrieved 26 March 2020.
  2. ↑ "Temixys- lamivudine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. Retrieved 13 February 2022.
  3. ↑ Waters L, Mehta V, Gogtay J, Boffito M (March 2021). "The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV". Journal of Virus Eradication. 7 (1): 100028. doi:10.1016/j.jve.2021.100028. PMC 7868802. PMID 33598310.
  4. ↑ "Drug Approval Package: Cimduo (lamivudine and tenofovir disoproxil fumarate)". U.S. Food and Drug Administration (FDA). 27 November 2018. Retrieved 26 March 2020.

Further reading


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.